Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This a multicenter, open-label, phase II clinical trial to assess the efficacy of
pembrolizumab in combination with eribulin in female patients older than 18 years old with
hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC) previously treated
with at least one, but not more than two, prior chemotherapeutic regimens for treatment of
locally recurrent and/or metastatic disease. Prior therapy must have included an
anthracycline and a taxane and prior anti-hormonal therapy is mandatory.
The number of patients to be included is 44 patients at 11 sites. All eligible patients will
be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23
mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle.